Want to see GB:PXS full AI Analyst Report?
Top Page
Provexis
(LSE:PXS)
Select Model
Select Model
Rating:45Neutral
Price Target:
0.78 p
▼(-25.71% Downside)
Action:Reiterated
Date:10/14/26
The score is primarily held back by weak financial performance—despite strong revenue growth, the company remains materially unprofitable with declining equity. Technicals are mixed with only modest trend support and slightly negative MACD. Valuation is also constrained by loss-making status (negative P/E) and no stated dividend yield.
Positive Factors
Revenue Growth
The 45.1% increase in 2026 revenue shows meaningful commercial expansion and improving scale. If this growth reflects durable demand for the company’s products, it can support operating leverage, broaden market reach, and create a stronger base for future profitability improvements.
Negative Factors
Persistent Losses
Continued operating and net losses indicate that revenue growth has not yet translated into a viable earnings model. A net margin near -40% leaves limited room for execution setbacks and means the company must improve margins materially before growth can produce durable shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The 45.1% increase in 2026 revenue shows meaningful commercial expansion and improving scale. If this growth reflects durable demand for the company’s products, it can support operating leverage, broaden market reach, and create a stronger base for future profitability improvements.
Read all positive factors
Provexis (PXS) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£18.77M
Dividend YieldN/A
Average Volume (3M)670.76K
Price to Earnings (P/E)―
Beta (1Y)-0.06
Revenue Growth-2.14%
EPS GrowthN/A
CountryUK
Employees2
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,345,891,400
10 Day Avg. Volume380,783
30 Day Avg. Volume670,761
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)22.91
Price to Sales (P/S)20.04
P/FCF Ratio140.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Provexis Business Overview & Revenue Model
Company Description
Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique ...
Provexis Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
46
Neutral
| Breakdown | Sep 2025 | Sep 2024 | Mar 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.26M | 1.29M | 801.96K | 389.92K | 426.17K |
| Gross Profit | 510.89K | 532.94K | 283.80K | 294.42K | 380.05K |
| EBITDA | -491.94K | -449.63K | 0.00 | 0.00 | 0.00 |
| Net Income | -502.76K | -452.72K | -586.24K | -385.24K | -224.25K |
Balance Sheet | |||||
| Total Assets | 1.30M | 1.01M | 498.04K | 845.99K | 1.13M |
| Cash, Cash Equivalents and Short-Term Investments | 893.14K | 708.09K | 189.36K | 379.12K | 863.87K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 722.92K | 248.21K | 307.45K | 188.34K | 157.91K |
| Stockholders Equity | 1.11M | 1.30M | 724.34K | 1.19M | 1.50M |
Cash Flow | |||||
| Free Cash Flow | 179.84K | -338.90K | -191.50K | -519.85K | -213.79K |
| Operating Cash Flow | 179.84K | -338.90K | -191.50K | -519.85K | -213.54K |
| Investing Cash Flow | 5.21K | 1.93K | 1.73K | 887.00 | 78.00 |
| Financing Cash Flow | 0.00 | 857.63K | 0.00 | 35.10K | 1.05M |
Provexis Technical Analysis
Negative
1.05
Price Trends
0.99
Negative
1.08
Negative
1.10
Negative
Market Momentum
-0.03
Positive
36.30
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PXS, the sentiment is Negative. The current price of 1.05 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 0.99, and below the 200-day MA of 1.10, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 36.30 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PXS.
Provexis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | £64.71M | 29.57 | 2.55% | 0.31% | 9.96% | 29.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | £60.69M | -7.72 | 64.57% | ― | 36.19% | 60.75% | |
45 Neutral | £18.77M | -80.00 | -44.68% | ― | -2.14% | ― | |
40 Underperform | £888.98K | >-0.01 | 233.76% | ― | ― | ― |
* Healthcare Sector Average
GB:PXS
Provexis
0.80
0.22
37.93%
GB:EAH
Eco Animal Health
95.50
12.50
15.06%
GB:CHLL
Chill Brands Group PLC
1.70
-8.80
-83.81%
GB:HELD
Mountfield
0.90
-0.05
-5.26%
GB:STX
Shield Therapeutics
5.65
-1.40
-19.86%
Provexis Corporate Events
Business Operations and StrategyFinancial Disclosures
Provexis rides surging Fruitflow demand as margins set to improve
Positive
Sep 30, 2026
Provexis reported annual revenue of £1.26m for the year to 31 March 2026, broadly flat year on year, but delivered a record £900k in second-half sales as demand for its Fruitflow heart-health ingredient accelerated among existing and new...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.